Search Results - "Duliege, Anne‐Marie"
-
1
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials
Published in American journal of hematology (01-07-2018)“…Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP)…”
Get full text
Journal Article -
2
Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
Published in American journal of hematology (01-05-2019)“…Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥50 000/μL) to fostamatinib in adults with long‐standing immune…”
Get full text
Journal Article -
3
A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia
Published in The New England journal of medicine (05-11-2009)“…This trial enlisted 14 patients with pure red-cell aplasia and antierythropoietin antibodies that were induced by treatment with conventional…”
Get full text
Journal Article -
4
Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients
Published in Clinical journal of the American Society of Nephrology (01-11-2011)“…Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent. We report the first assessment of its efficacy and…”
Get full text
Journal Article -
5
Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers
Published in Journal of clinical pharmacology (01-01-2008)“…Peptidic erythropoiesis receptor agonist is a synthetic, PEGylated peptide that can promote red blood cell production upon binding to the erythropoietin…”
Get full text
Journal Article -
6
Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers
Published in The Journal of infectious diseases (01-05-2001)“…Live attenuated viral vectors that express human immunodeficiency virus (HIV) antigens are being developed as potential vaccines to prevent HIV infection. The…”
Get full text
Journal Article -
7
Clade B-Based HIV-1 Vaccines Elicit Cross-Clade Cytotoxic T Lymphocyte Reactivities in Uninfected Volunteers
Published in Proceedings of the National Academy of Sciences - PNAS (18-02-1997)“…A fundamental goal of current strategies to develop an efficacious vaccine for AIDS is the elicitation of broadly reactive cytotoxic T lymphocyte (CTL)…”
Get full text
Journal Article -
8
Effect of Previous or Simultaneous Immunization with Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine plus MF59 in Healthy CMV-Seronegative Adults
Published in The Journal of infectious diseases (01-03-2002)“…Development of a vaccine for prevention of congenital cytomegalovirus (CMV) disease is a priority. This study evaluated a “prime-boost” strategy by comparing…”
Get full text
Journal Article -
9
Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia
Published in The American journal of managed care (01-11-2019)“…Immune thrombocytopenia (ITP) is an autoimmune disease associated with substantial heterogeneity and varying outcomes. Significant bleeding, including…”
Get full text
Journal Article -
10
Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
Published in The New England journal of medicine (24-01-2013)“…Two studies compared peginesatide with darbepoetin in patients with CKD and anemia who were not receiving dialysis. The agents were similar in increasing and…”
Get full text
Journal Article -
11
Peginesatide in Patients with Anemia Undergoing Hemodialysis
Published in The New England journal of medicine (24-01-2013)“…In two randomized, controlled studies involving patients undergoing long-term hemodialysis, peginesatide, a synthetic peptide-based erythropoiesis-stimulating…”
Get full text
Journal Article -
12
Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults
Published in The Journal of infectious diseases (15-07-2003)“…Safety and immunogenicity of 2 recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and…”
Get full text
Journal Article -
13
An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
Published in BMC nephrology (30-08-2012)“…Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer…”
Get full text
Journal Article -
14
Human Immunodeficiency Virus Type 1 (HIV-1) gp120–Specific Antibodies in Neonates Receiving an HIV-1 Recombinant gp120 Vaccine
Published in The Journal of infectious diseases (15-11-2001)“…Infants born to human immunodeficiency virus type 1 (HIV-1)–infected mothers were immunized at birth and at ages 4, 12, and 20 weeks with low-, medium-, or…”
Get full text
Journal Article -
15
Peginesatide for Anemia in Chronic Kidney Disease
Published in The New England journal of medicine (18-04-2013)“…To the Editor: Macdougall et al. (Jan 24. issue) 1 report that cardiovascular events were increased with peginesatide in patients who were not receiving…”
Get full text
Journal Article -
16
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers
Published in Blood (15-09-2006)“…Hematide is an investigational pegylated synthetic peptide that stimulates erythropoiesis in animal models and is being developed for the treatment of anemia…”
Get full text
Journal Article -
17
Lymphoproliferative Responses to Recombinant HIV-1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines
Published in The Journal of infectious diseases (01-03-2000)“…Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of…”
Get full text
Journal Article -
18
Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy
Published in Kidney international reports (01-12-2023)“…We reported increased spleen tyrosine kinase (SYK) expression in kidney biopsies of patients with IgA nephropathy (IgAN) and that inhibition of SYK reduces…”
Get full text
Journal Article -
19
A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant
Published in The Journal of infectious diseases (01-10-1999)“…A phase I randomized, double-blind, placebo-controlled trial was done with a cytomegalovirus (CMV) vaccine based on the envelope glycoprotein, gB, combined…”
Get full text
Journal Article -
20
Neutralization of a Clade B Primary Isolate by Sera from Human Immunodeficiency Virus-Uninfected Recipients of Candidate AIDS Vaccines
Published in The Journal of infectious diseases (01-04-1997)“…The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV- 1) vaccines to neutralize HIV-1 primary isolates may be due to a…”
Get full text
Journal Article